TOVX Theriva Biologics, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 894158 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY66.7%
TTM EPS YoY-44.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-99.8%
ROA-28.0%
ROIC (approx.)-956.5%
Asset turnover—
Leverage & solvency
Liabilities / assets65.9%
Debt / equity0.00x
Current ratio1.21x
Interest coverage-138.77x
Cash quality & payout
Operating cash flow / net income1.29x
Accruals ratio8.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q3*2026-09-30 | 2026Q2*2026-06-30 | 2026Q1*2026-03-31 | 2025Q4*2025-12-31 | 2025Q3*2025-09-30 | 2025Q2*2025-06-30 | 2025Q1*2025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | $0 | $300,000 | — | — | — | — | — |
| R&D expense | $612,000 | $1.27M | $355,000 | $1.13M | $2.55M | $1.95M | $2.97M | $2.89M |
| SG&A expense | $923,000 | $2.03M | $2.07M | $931,000 | $1.89M | $11.18M | $1.45M | $1.69M |
| Operating income | -$1.53M | -$3.29M | -$2.13M | -$2.06M | -$4.44M | -$13.13M | -$4.42M | -$4.58M |
| Interest expense | $16,000 | $17,000 | $16,000 | $16,000 | $16,000 | $16,000 | $12,000 | — |
| Pretax income | -$1.47M | -$3.22M | -$2.04M | -$2.00M | -$4.36M | -$13.06M | -$4.32M | -$4.45M |
| Net income | -$1.47M | -$3.22M | -$2.04M | -$2.00M | -$4.36M | -$13.06M | -$4.32M | -$4.45M |
| EBITDA | -$1.51M | -$3.27M | -$2.10M | -$2.04M | -$4.41M | -$13.11M | -$4.39M | -$4.55M |
| EPS (basic) | -0.03 | -0.07 | -0.05 | — | -0.45 | -1.93 | -1.55 | — |
| EPS (diluted) | -0.03 | -0.07 | -0.05 | — | -0.45 | -1.93 | -1.55 | — |
| Weighted avg. shares (diluted) | 45.89M | 45.89M | 41.07M | — | 9.68M | 6.75M | 2.78M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $8.47M | $11.34M | $14.43M | $13.06M | $7.53M | $12.12M | $10.01M | $11.71M |
| Current assets | $10.62M | $13.67M | $16.76M | $17.47M | $9.90M | $14.74M | $12.48M | $16.28M |
| PP&E, net | $155,000 | $173,000 | $194,000 | $222,000 | $249,000 | $258,000 | $253,000 | $270,000 |
| Goodwill | — | — | — | — | — | — | — | $0 |
| Intangibles | $18.96M | $19.06M | $19.23M | $19.62M | $19.61M | $19.62M | $18.08M | $17.36M |
| Total assets | $31.56M | $34.86M | $38.25M | $38.24M | $30.84M | $35.83M | $32.16M | $35.35M |
| Current liabilities | $8.78M | $12.11M | $10.26M | $10.01M | $11.00M | $12.39M | $8.15M | $7.58M |
| Long-term debt | — | — | — | $1.67M | — | — | — | $92,000 |
| Total debt | — | — | — | $1.67M | — | — | — | $92,000 |
| Total liabilities | $20.81M | $22.67M | $22.85M | $22.86M | $24.10M | $25.21M | $16.66M | $16.29M |
| Shareholders' equity | $10.75M | $12.19M | $15.40M | $15.38M | $6.74M | $10.62M | $15.50M | $19.07M |
| Net debt | — | — | — | -$11.38M | — | — | — | -$11.61M |
| Shares outstanding | 45.89M | 45.89M | 45.89M | 35.69M | 10.30M | 9.06M | 2.78M | 2.78M |
| Cash flow statement | ||||||||
| Operating cash flow | -$2.86M | -$3.08M | -$2.46M | -$2.88M | -$4.32M | -$4.71M | -$4.76M | -$4.69M |
| Capital expenditure | $5,000 | — | — | $0 | $19,000 | — | — | $0 |
| Free cash flow | -$2.87M | — | — | -$2.88M | -$4.34M | — | — | -$4.69M |
| Investing cash flow | -$5,000 | — | — | $0 | -$19,000 | — | — | $0 |
| Financing cash flow | -$6,000 | -$14,000 | $3.87M | $8.46M | -$148,000 | $6.81M | $3.07M | $7,000 |
| Depreciation & amortization | $22,000 | $24,000 | $24,000 | $27,000 | $28,000 | $27,000 | $26,000 | $27,000 |
| Stock-based compensation | $144,000 | $135,000 | $135,000 | $153,000 | $228,000 | $173,000 | $100,000 | $162,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.